Recovery & Repair · 11-aa EPO-derived peptide · Compounded 503A
ARA-290 (Cibinetide): the tissue-protective EPO derivative.
ARA-290 (also called cibinetide) is an 11-amino-acid peptide derived from the helix-B region of erythropoietin. It preserves erythropoietin's tissue-protective and anti-inflammatory activity without the red-cell-stimulating effects — making it one of the most clinically studied investigational peptides for small-fiber neuropathy and inflammatory tissue injury.
Free shipping over $150 · Pay with card or crypto
What ARA-290 is
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B region of erythropoietin (EPO). It activates the heteromeric 'innate repair receptor' (IRR) — composed of the EPO receptor and the common beta chain (CD131) — that mediates EPO's tissue-protective effects.
Critically, ARA-290 does not bind the homodimeric EPO receptor that drives red blood cell production. This separates the tissue-protective activity from the hematopoietic activity — eliminating the thrombotic risk of conventional erythropoietin therapy.
It has been studied in Phase 2 trials for small-fiber neuropathy in sarcoidosis and type 2 diabetes — the indications where the human data is strongest.
How it works
ARA-290 activates the innate repair receptor (IRR), a heteromeric receptor expressed on tissues responding to injury. IRR activation drives anti-apoptotic, anti-inflammatory, and pro-regenerative gene programs.
In small-fiber neuropathy, ARA-290 supports intraepidermal nerve fiber density and reduces neuropathic pain — the mechanism behind its Phase 2 clinical signal in sarcoidosis-associated small-fiber neuropathy.
By avoiding the homodimeric EPO receptor entirely, ARA-290 does not raise hematocrit and does not carry the thrombotic risk profile of EPO — addressing the central safety limitation that limits conventional erythropoietin's use in non-anemia indications.
What patients use it for
Small-fiber neuropathy
The signature clinical use — Phase 2 trials in sarcoidosis-associated small-fiber neuropathy demonstrated improvement in nerve fiber density and neuropathic symptoms.
Nerve repair
Broader nerve-repair activity in preclinical models supports investigational use in diabetic peripheral neuropathy and post-injury nerve regeneration.
Anti-inflammatory
Tissue-level anti-inflammatory activity through innate repair receptor signaling, distinct from systemic immunosuppression.
No erythropoietic risk
The structural separation of tissue protection from hematopoiesis is the defining advantage — no rise in hematocrit, no thrombotic risk.
Evidence summary
Brines M et al. (PNAS, 2008) — the original publication establishing helix-B-derived peptides as tissue-protective without erythropoietic activity.
Heij L et al. (Molecular Medicine, 2012) — Phase 2 trial of ARA-290 in sarcoidosis-associated small-fiber neuropathy, demonstrating clinical improvement.
Dahan A et al. (Molecular Medicine, 2013) reported analgesic and tissue-protective effects of ARA-290 in additional human studies.
Honest framing: ARA-290 has more direct human Phase 2 clinical trial data than most investigational peptides in this category. Real evidence in small-fiber neuropathy.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly subcutaneous injection. Clinical trial dosing has typically been 4 mg daily.
Course-based use of weeks to months is typical, depending on indication.
Compounded ARA-290 from licensed 503A pharmacies is the typical U.S. dispensing pathway. Not FDA-approved.
Safety and contraindications
Notable safety advantage — no erythropoietic activity means no rise in hematocrit and no thrombotic risk, unlike conventional erythropoietin.
Generally well-tolerated in the Phase 2 trial program. Most reported adverse events were mild local injection-site reactions.
Contraindications: pregnancy, lactation, known hypersensitivity. Use under physician supervision.
Who it's typically considered for
- Adults with documented small-fiber neuropathy (sarcoidosis, diabetes, idiopathic) under specialist supervision
- Patients with chronic neuropathic pain syndromes
- Adults with chronic inflammatory tissue injury where systemic immunosuppression is not desired
- Patients comfortable with the honest evidence framing — real Phase 2 data, not FDA-approved
Frequently asked questions
Is ARA-290 FDA-approved?
No. ARA-290 (cibinetide) has been studied in Phase 2 trials but has not received FDA approval. Compounded ARA-290 is prepared by licensed 503A pharmacies under physician prescription for off-label use.
Will ARA-290 raise my red blood cell count?
No. The defining feature is tissue protection without erythropoietic activity. ARA-290 does not bind the receptor that drives red cell production — that's the central structural advantage over conventional EPO.
How long until results in neuropathy?
The Phase 2 trial endpoints in small-fiber neuropathy were typically measured at 4–28 days for symptom changes and 12+ weeks for nerve fiber density changes.
ARA-290 vs BPC-157?
Different mechanisms and indications. BPC-157 broadly supports connective tissue and gut healing. ARA-290 is specifically tissue-protective at the nerve/inflammation level through innate repair receptor signaling.
Can ARA-290 help diabetic neuropathy?
Preclinical and early clinical data support investigational use in diabetic peripheral neuropathy. The mechanism is well-aligned; direct RCT data in diabetes-associated neuropathy is limited.
Is ARA-290 immunosuppressive?
Not in the conventional sense — it does not broadly suppress systemic immune function. Its anti-inflammatory activity is local and receptor-mediated, distinct from conventional immunosuppressants.
Is ARA-290 safe long-term?
Long-term safety data is limited beyond the Phase 2 trial windows. Periodic reassessment is appropriate.
Sources
- Brines M et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. PNAS (2008). — pubmed.ncbi.nlm.nih.gov/18632561
- Heij L et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Molecular Medicine (2012). — pubmed.ncbi.nlm.nih.gov/22735755
- Dahan A et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine (2013). — pubmed.ncbi.nlm.nih.gov/23508573
- Brines M, Cerami A. The receptor that tames the innate immune response. Molecular Medicine (2012). — pubmed.ncbi.nlm.nih.gov/22451068
Considering ARA-290?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.